Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 92,150,592
  • Shares Outstanding, K 1,306,730
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.20
  • Price/Sales 3.03
  • Price/Cash Flow 5.60
  • Price/Book 4.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.76 +10.60%
on 06/16/17
71.44 -1.29%
on 06/22/17
+5.83 (+9.01%)
since 05/23/17
3-Month
63.76 +10.60%
on 06/16/17
71.44 -1.29%
on 06/22/17
+3.03 (+4.49%)
since 03/23/17
52-Week
63.76 +10.60%
on 06/16/17
88.85 -20.63%
on 07/25/16
-12.85 (-15.41%)
since 06/23/16

Most Recent Stories

More News
Stock Market News for June 23, 2017

The Nasdaq finished in the green for consecutive sessions on Thursday, boosted primarily by gain in health care shares

USB : 50.77 (-1.03%)
E : 30.50 (+0.69%)
BBBY : 29.65 (-12.12%)
GILD : 70.52 (+0.06%)
GS : 217.19 (-1.17%)
UNH : 185.25 (-0.67%)
European CHMP Adopts Positive Opinion for Gilead's Vosevi(R) (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted...

GILD : 70.52 (+0.06%)
How to Find the Best Value Stocks

A great value stock isn't just a cheap stock. Tracey uses a "secret sauce" to find the hidden gems among the cheap stocks.

AMAT : 44.09 (+1.73%)
MHO : 27.69 (+0.40%)
ICHR : 23.35 (+3.27%)
GILD : 70.52 (+0.06%)
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.52% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $65.61 to a high of $67.27. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of...

GILD : 70.52 (+0.06%)
Gilead Sciences Rises 2.52% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $65.61 to a high of $67.27. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of...

GILD : 70.52 (+0.06%)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $66.39

Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $65.20 today and has reached the first level of resistance at $66.39. Should the shares continue to rise, the resistance pivots of...

GILD : 70.52 (+0.06%)
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

CELG : 134.31 (+0.47%)
VRTX : 133.50 (-1.50%)
CLVS : 95.00 (-1.84%)
GILD : 70.52 (+0.06%)
SGEN : 61.74 (-2.39%)
REGN : 517.33 (-1.75%)
AMGN : 172.50 (-0.76%)
BIIB : 280.32 (-0.09%)
Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Gilead Sciences and Sarepta Therapeutics

NEW YORK, NY / ACCESSWIRE / June 21, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process...

SRPT : 35.02 (-1.30%)
GILD : 70.52 (+0.06%)
XBI : 80.31 (+1.40%)
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

VVUS : 1.22 (+5.17%)
NVS : 86.34 (unch)
GILD : 70.52 (+0.06%)
BMY : 56.64 (-1.20%)
Gilead Sciences Falls 1.43% on Heavy Volume: Watch For Potential Rebound

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $63.76 to a high of $64.84. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $64.10...

GILD : 70.52 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 72.11
1st Resistance Point 71.31
Last Price 70.52
1st Support Level 69.78
2nd Support Level 69.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.